Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
暂无分享,去创建一个
[1] Success rates in the United States drug development system , 1984, Clinical pharmacology and therapeutics.
[2] L Lasagna,et al. Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.
[3] L Lasagna,et al. New drug development in the United States from 1963 to 1990 , 1991, Clinical pharmacology and therapeutics.
[4] G. Tadmor,et al. Biopharmaceuticals and Conventional Drugs: Clinical Success Rates , 1992, Bio/Technology.
[5] Mark-M. Struck,et al. Biopharmaceutical R&D Success Rates and Development Times , 1994, Bio/Technology.
[6] J. DiMasi,et al. Success rates for new drugs entering clinical testing in the United States , 1995, Clinical pharmacology and therapeutics.
[7] Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. , 1995, PharmacoEconomics.
[8] J. DiMasi,et al. Recombinant protein and therapeutic monoclonal antibody drug development in the United States from 1980 to 1994 , 1996, Clinical pharmacology and therapeutics.
[9] J. DiMasi. New drug development in the United States from 1963 to 1999 , 2001, Clinical pharmacology and therapeutics.
[10] J. DiMasi,et al. Risks in new drug development: Approval success rates for investigational drugs , 2001, Clinical pharmacology and therapeutics.
[11] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[12] R. Frank,et al. New estimates of drug development costs. , 2003, Journal of health economics.
[13] K. Kaitin,et al. The New Drug Approvals of 1999, 2000, and 2001: Drug Development Trends a Decade after Passage of the Prescription Drug User Fee Act of 1992 , 2003 .
[14] Henry G. Grabowski,et al. R&D Costs and Returns by Therapeutic Category , 2004 .
[15] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[16] J. DiMasi,et al. The cost of biopharmaceutical R&D: is biotech different? , 2007 .
[17] Janice M Reichert,et al. Monoclonal antibodies as innovative therapeutics. , 2008, Current pharmaceutical biotechnology.
[18] Kenneth A Getz,et al. Assessing the Impact of Protocol Design Changes on Clinical Trial Performance , 2008, American journal of therapeutics.
[19] J. DiMasi. The Value of Improving the Productivity of the Drug Development Process , 2012, PharmacoEconomics.